Immutep Faces Securities Claims Investigation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 19 2026
0mins
Should l Buy IMMP?
Source: Globenewswire
- Investigation Launched: Rosen Law Firm has announced an investigation into Immutep Ltd. (NASDAQ: IMMP) due to potential misleading business information issued to investors, which may lead to significant securities claims against the company.
- Stock Price Plunge: Following the Independent Data Monitoring Committee's recommendation to discontinue the TACTI-004 Phase III study on March 13, 2026, Immutep's American Depositary Receipt (ADR) price fell by $2.28, or 82.6%, closing at $0.48, severely impacting investor confidence.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to recover investor losses, allowing affected shareholders to participate without any upfront fees, which may encourage broader participation from impacted investors.
- Firm's Reputation: Known for its successful track record in securities class actions, Rosen Law Firm recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases effectively.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMMP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMMP
Wall Street analysts forecast IMMP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.446
Low
12.00
Averages
12.00
High
12.00
Current: 0.446
Low
12.00
Averages
12.00
High
12.00
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Shareholder Class Action Filed Against Immutep Limited
- Lawsuit Background: Immutep Limited (NASDAQ: IMMP) is facing a shareholder class action lawsuit alleging false and misleading statements regarding the status and prospects of its TACTI-004 trial, highlighting serious investor concerns about the company's transparency.
- Investor Losses: The lawsuit targets investors who purchased Immutep shares between March 24, 2025, and March 12, 2026, encouraging those who experienced losses during this period to contact legal counsel, reflecting investor unease about the company's future.
- Legal Representation: Holzer & Holzer, LLC, a highly rated law firm in securities litigation, is dedicated to vigorously representing shareholders and investors, underscoring the firm's commitment to protecting investor rights in the face of corporate misconduct.
- Lawsuit Deadline: Investors must apply to be appointed lead plaintiff by July 6, 2026, emphasizing the importance of timely action to ensure their rights are protected in the litigation process.
See More
Immutep Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Immutep, seeking damages for investors who purchased securities between March 24, 2025, and March 12, 2026, reflecting strong investor concerns over potential fraud.
- False Statements Allegations: The complaint alleges that Immutep misrepresented the status and prospects of the TACTI-004 trial, particularly by relying on prior positive results to create an unfounded optimism, severely undermining investor confidence in the company's future.
- Increased Risk Warning: According to the lawsuit, executives at Immutep were aware of the significantly increased risk that the TACTI-004 trial would fail to meet its primary efficacy and safety endpoints, yet they failed to disclose this critical information to investors, potentially leading to substantial losses.
- Investor Rights Protection: Investors have until July 6, 2026, to apply to be lead plaintiffs, with the law firm offering legal support on a contingency fee basis, demonstrating a commitment to protecting investor rights and interests.
See More
Class Action Lawsuit Filed for Immutep ADRs
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, with a deadline of July 6, 2026, for potential lead plaintiffs, highlighting the urgency and opportunity for compensation.
- Lawsuit Background: The lawsuit alleges that Immutep concealed critical internal data regarding the TACTI-004 clinical trial, despite claims of strong progress, resulting in investor losses when the truth was revealed, indicating significant deficiencies in the company's transparency.
- Law Firm's Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, which enhances investor confidence in the firm's capability to handle this case effectively.
- Investor Action Steps: Investors are encouraged to visit the Rosen Law Firm's website or call their toll-free number for more information, demonstrating the firm's proactive approach in supporting investors and ensuring their rights are protected.
See More
Rosen Law Firm Investigates Immutep Securities Fraud Claims
- Securities Fraud Investigation: The Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ:IMMP) for allegedly issuing materially misleading business information, indicating that investors may be entitled to compensation if they purchased Immutep securities.
- Class Action Preparation: The firm is preparing a class action lawsuit aimed at recovering investor losses without requiring any upfront fees, demonstrating a strong commitment to protecting investor rights.
- Stock Price Plunge: On March 13, 2026, Immutep's American Depositary Receipt (ADR) price fell by $2.28, or 82.6%, to close at $0.48 after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, significantly impacting the company's market value.
- Firm's Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strength and extensive experience in the securities litigation field.
See More
Immutep Faces Investor Misleading Allegations
- Lawsuit Background: On May 5, 2026, a class action was filed against Immutep Limited (IMMP), alleging that the company misled investors regarding the efficacy and viability of its drug candidates between March 24, 2025, and March 12, 2026, resulting in significant investor losses.
- Clinical Trial Issues: The TACTI-004 clinical trial was recommended for discontinuation by the Independent Data Monitoring Committee on March 13, 2026, due to failure to meet primary efficacy and safety endpoints, indicating the company's concealment and misrepresentation of internal clinical data.
- Stock Price Plunge: Following the announcement of the trial's discontinuation, Immutep's ADR price plummeted from $2.76 per share on March 12, 2026, to $0.48 per share, reflecting an 83% decline and severely undermining investor confidence in the company's future prospects.
- Legal Implications: Investors are eligible to submit documents by July 6, 2026, to serve as lead plaintiffs in the class action, highlighting the urgent need for accountability in corporate governance and executive responsibility.
See More
Immutep Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Immutep for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between March 24, 2025, and March 12, 2026, with a deadline to contact the firm by July 6, 2026, to participate.
- False Statements Exposed: The complaint alleges that Immutep concealed the results of its TACTI-004 trial for eftilagimod alfa, as the company claimed in a Form-K filed with the SEC on January 30, 2026, that the trial was showing “strong operational progress,” despite knowing it would fail to meet primary efficacy endpoints.
- Investor Losses: When the market learned the truth about Immutep, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, potentially leading to a decline in investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to reach out to discuss their rights, highlighting the firm's focus on securities class action lawsuits aimed at helping investors recover losses.
See More
Shareholder Class Action Filed Against Immutep Limited
- Lawsuit Background: Immutep Limited (NASDAQ: IMMP) is facing a shareholder class action lawsuit alleging false and misleading statements regarding the status and prospects of its TACTI-004 trial, highlighting serious investor concerns about the company's transparency.
- Investor Losses: The lawsuit targets investors who purchased Immutep shares between March 24, 2025, and March 12, 2026, encouraging those who experienced losses during this period to contact legal counsel, reflecting investor unease about the company's future.
- Legal Representation: Holzer & Holzer, LLC, a highly rated law firm in securities litigation, is dedicated to vigorously representing shareholders and investors, underscoring the firm's commitment to protecting investor rights in the face of corporate misconduct.
- Lawsuit Deadline: Investors must apply to be appointed lead plaintiff by July 6, 2026, emphasizing the importance of timely action to ensure their rights are protected in the litigation process.
See More
Immutep Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Immutep, seeking damages for investors who purchased securities between March 24, 2025, and March 12, 2026, reflecting strong investor concerns over potential fraud.
- False Statements Allegations: The complaint alleges that Immutep misrepresented the status and prospects of the TACTI-004 trial, particularly by relying on prior positive results to create an unfounded optimism, severely undermining investor confidence in the company's future.
- Increased Risk Warning: According to the lawsuit, executives at Immutep were aware of the significantly increased risk that the TACTI-004 trial would fail to meet its primary efficacy and safety endpoints, yet they failed to disclose this critical information to investors, potentially leading to substantial losses.
- Investor Rights Protection: Investors have until July 6, 2026, to apply to be lead plaintiffs, with the law firm offering legal support on a contingency fee basis, demonstrating a commitment to protecting investor rights and interests.
See More
Class Action Lawsuit Filed for Immutep ADRs
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, with a deadline of July 6, 2026, for potential lead plaintiffs, highlighting the urgency and opportunity for compensation.
- Lawsuit Background: The lawsuit alleges that Immutep concealed critical internal data regarding the TACTI-004 clinical trial, despite claims of strong progress, resulting in investor losses when the truth was revealed, indicating significant deficiencies in the company's transparency.
- Law Firm's Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, which enhances investor confidence in the firm's capability to handle this case effectively.
- Investor Action Steps: Investors are encouraged to visit the Rosen Law Firm's website or call their toll-free number for more information, demonstrating the firm's proactive approach in supporting investors and ensuring their rights are protected.
See More
Rosen Law Firm Investigates Immutep Securities Fraud Claims
- Securities Fraud Investigation: The Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ:IMMP) for allegedly issuing materially misleading business information, indicating that investors may be entitled to compensation if they purchased Immutep securities.
- Class Action Preparation: The firm is preparing a class action lawsuit aimed at recovering investor losses without requiring any upfront fees, demonstrating a strong commitment to protecting investor rights.
- Stock Price Plunge: On March 13, 2026, Immutep's American Depositary Receipt (ADR) price fell by $2.28, or 82.6%, to close at $0.48 after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, significantly impacting the company's market value.
- Firm's Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strength and extensive experience in the securities litigation field.
See More
Immutep Faces Investor Misleading Allegations
- Lawsuit Background: On May 5, 2026, a class action was filed against Immutep Limited (IMMP), alleging that the company misled investors regarding the efficacy and viability of its drug candidates between March 24, 2025, and March 12, 2026, resulting in significant investor losses.
- Clinical Trial Issues: The TACTI-004 clinical trial was recommended for discontinuation by the Independent Data Monitoring Committee on March 13, 2026, due to failure to meet primary efficacy and safety endpoints, indicating the company's concealment and misrepresentation of internal clinical data.
- Stock Price Plunge: Following the announcement of the trial's discontinuation, Immutep's ADR price plummeted from $2.76 per share on March 12, 2026, to $0.48 per share, reflecting an 83% decline and severely undermining investor confidence in the company's future prospects.
- Legal Implications: Investors are eligible to submit documents by July 6, 2026, to serve as lead plaintiffs in the class action, highlighting the urgent need for accountability in corporate governance and executive responsibility.
See More
Immutep Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Immutep for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between March 24, 2025, and March 12, 2026, with a deadline to contact the firm by July 6, 2026, to participate.
- False Statements Exposed: The complaint alleges that Immutep concealed the results of its TACTI-004 trial for eftilagimod alfa, as the company claimed in a Form-K filed with the SEC on January 30, 2026, that the trial was showing “strong operational progress,” despite knowing it would fail to meet primary efficacy endpoints.
- Investor Losses: When the market learned the truth about Immutep, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, potentially leading to a decline in investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to reach out to discuss their rights, highlighting the firm's focus on securities class action lawsuits aimed at helping investors recover losses.
See More
